This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Chiesi Ltd.
Chiesi Ltd., a subsidiary of the Chiesi Group, is a prominent player in the global pharmaceutical industry, headquartered in Great Britain. Founded in 1935, the company has established itself as a leader in the development of innovative therapies, particularly in the fields of respiratory, neonatology, and rare diseases. With a strong presence across Europe and expanding operations in other regions, Chiesi Ltd. is committed to improving patient outcomes through its unique portfolio of products. The company is renowned for its cutting-edge inhalation therapies and advanced drug delivery systems, which set it apart in a competitive market. Chiesi Ltd. has achieved significant milestones, including recognition for its sustainable practices and commitment to research and development. As a result, it holds a notable position within the pharmaceutical sector, dedicated to enhancing the quality of life for patients worldwide.
DitchCarbon Score
How does Chiesi Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Chiesi Ltd.'s score of 76 is higher than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Chiesi Ltd., headquartered in Great Britain, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Chiesi Farmaceutici S.p.A., which may influence its climate commitments and emissions reporting. Chiesi Ltd. inherits its climate initiatives and targets from its parent company, Chiesi Farmaceutici S.p.A. This includes participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), although specific reduction targets or achievements have not been detailed. As part of its commitment to sustainability, Chiesi Farmaceutici S.p.A. has set ambitious climate goals, which may also apply to Chiesi Ltd. However, without specific emissions data or reduction targets disclosed, the exact impact of these initiatives on Chiesi Ltd.'s carbon footprint remains unclear. Overall, while Chiesi Ltd. is aligned with broader corporate sustainability efforts, further details on its individual emissions and climate commitments are not currently available.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 21,729,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 17,985,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Chiesi Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
